Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

• Wonngarm Kittanamongkolchai,
• Yong Poovorawan,
• Theerada Assawasaksakul,
• Seelwan Sathitratanacheewin,
• Preeyaporn Vichaiwattana,
• Nasamon Wanlapakorn

Affiliations

Wonngarm Kittanamongkolchai

Mahachakri Sirindhorn Clinical Research Center, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Yong Poovorawan

Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Theerada Assawasaksakul

Division of Rheumatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Seelwan Sathitratanacheewin

Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Preeyaporn Vichaiwattana

Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Nasamon Wanlapakorn

Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand